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OBJECTIVES The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial was a
multicenter trial of atrioventricular junction ablation and pacing (AVJAP) compared with
pharmacologic ventricular rate control (medication [MED]) in patients with mild to
moderately symptomatic permanent atrial fibrillation (AF).
BACKGROUND There have been very few prospective randomized trials, undertaken in highly symptomatic
patients, comparing AVJAP with pharmacologic methods of ventricular rate control for
patients with permanent AF.
METHODS There were 99 patients (70 men, mean age 68 8.6 years) at five centers. Forty-nine patients
were randomized to AVJAP while 50 patients were randomized to pharmacologic control.
The primary end point was cardiac function measured by echocardiography and exercise
tolerance. The secondary end points were ventricular rate control, evaluated by 24-h
ambulatory electrocardiographic monitoring, and quality of life. Data were collected at
randomization and then at one month, six months, and 12 months post-randomization.
RESULTS At 12 months follow-up there was no significant difference in left ventricular ejection fraction
(AVJAP: 54  17%; MED: 61  13% [p  ns]) or exercise duration on treadmill testing
(AVJAP: 4.1  2 min; MED: 4.6  2 min [p  ns]); however, the peak ventricular rate was
lower in the AVJAP group during exercise (112  17 beats/min vs. 153  36 beats/min, p
 0.05) and activities of daily life (117  16 beats/min vs. 152  37 beats/min, p  0.05).
The CAST quality-of-life questionnaire revealed that patients in the AVJAP group had fewer
symptoms at six months (p  0.003) and at 12 months (p  0.004). The observed relative
risk reduction in symptoms at 12 months was 18%. Global subjective semiquantitative
measurement of quality of life using the “ladder of life” revealed that the AVJAP group
reported a 6% better quality of life at six months (p  0.011).
CONCLUSIONS In this trial, AVJAP for patients with mild to moderately symptomatic permanent AF did not
worsen cardiac function during long-term follow-up, and quality of life was improved. (J Am
Coll Cardiol 2003;41:1697–702i) © 2003 by the American College of Cardiology Foundation
Atrial fibrillation (AF) is the most common chronic tachy-
arrhythmia, affecting 5% of people over the age of 60 (1).
Ventricular rate control is a major treatment aim for patients
with permanent AF. Although several studies have com-
See page 1703
pared atrioventricular junction ablation and pacing (AVJAP)
with pharmacologic ventricular rate control in AF, earlier
studies were not randomized (2–4), and the few published
randomized prospective studies comparing the two treat-
ment options have included very symptomatic patients with
a mean left ventricular ejection fraction (LVEF) 50 (5,6).
The Australian Intervention Randomized Control of
Rate in Atrial Fibrillation Trial (AIRCRAFT) was a multi-
center, prospective randomized trial of AVJAP versus pharma-
cologic treatment for ventricular rate control and was under-
taken in patients with permanent AF who had mild to
moderate symptoms, preserved LVEF, and a ventricular rate
that was controlled pharmacologically. AVJAP has not been
compared to pharmacologic therapy in this population, which
represents the great majority of patients with permanent AF.
The primary end point was cardiac function measured by
echocardiography and exercise tolerance. The secondary end
points included ventricular rate control, evaluated by 24-h
ambulatory electrocardiographic monitoring, and quality of
life (QoL).
METHODS
Study protocol. The study protocol was approved by the
ethics committees of all participating hospitals. The study
was completely explained to each prospective patient before
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he or she consented, in writing, to participate in any
study-related procedures. Ethics committee approval for the
study was obtained in May 1998 and the first patient was
enrolled in June 1998. The last patient completed follow-up
in July 2001.
The study inclusion criteria were: 1) age 40 years, 2)
symptomatic permanent AF (12 months or with failed
cardioversion or medication therapy) with uncontrolled
ventricular rate in which a good rate control (defined as rest
heart rate [HR] 80 and exercise HR 150) could be
achieved by drugs during a three-month screening period,
3) ability to give informed consent, and 4) ability to perform
a treadmill test.
The exclusion criteria were: 1) clinical indication for
ablation and pacing; 2) the likelihood of surgery or trans-
catheter valvuloplasty within 12 months of enrollment; 3)
untreated resting mean ventricular rate 80 beats/min
(averaged over 1 min on three separate occasions) and150
beats/min during maximum exercise (averaged over 1 min
during a treadmill test using the modified Bruce protocol);
4) unstable angina pectoris; 5) Wolff-Parkinson-White
syndrome; 6) severe tricuspid valvular regurgitation (by echo
criteria) or tricuspid prosthetic valve; 7) New York Heart
Association functional class IV despite pharmacologic treat-
ment; 8) unwillingness or inability to cooperate or to give
informed consent; 9) any other serious medical condition
(such as terminal illness) that, in the opinion of the
investigator, would preclude optimal participation in the
study; 10) an occupation or hobby that precluded permanent
pacing; and 11) inability to travel to the study center for
follow-up.
Upon entry into the trial all patients had intensive
medical therapy directed by a cardiologist for three months
before randomization in an attempt to maximize pharma-
cologic ventricular rate control. Successful ventricular rate
control was arbitrarily defined as a resting mean ventricular
rate 80 beats/min (measured during a period of 1 min on
three separate occasions) and 150 beats/min during max-
imum tolerated exercise (during a treadmill test using a
modified Bruce protocol). Randomization was conducted
independently by the biostatistical consulting service of the
University of Western Australia. Patients were stratified
according to echocardiographic estimation LVEF 45% or
45% at the end of the initial three-month observation
period. The randomization code was computer generated
and was balanced within each site as well as for LVEF
45% or45%. Patients were randomized regardless of the
clinical results of the period of intensive medical manage-
ment, and the randomization code was hidden from the
treating cardiologist until the time of allocation.
Pharmacologic treatment. In the pharmacologic treat-
ment group, drugs were prescribed to achieve satisfactory
control of the ventricular rate. Drugs used for ventricular
rate control included digoxin, metoprolol, atenolol, vera-
pamil, and diltiazem either alone or in combination. The
choice of drugs was at the discretion of the treating
clinician. Patient compliance was monitored by patient
interview at each visit.
Catheter ablation and pacing. In the AVJAP group pa-
tients underwent a combined ablation and pacemaker inser-
tion procedure. For atrioventricular junction ablation a
deflectable tip ablation catheter was positioned across the
tricuspid annulus to record atrial and ventricular electro-
grams and a His bundle potential. Radiofrequency energy
was then delivered with power and duration determined by
impedance response or catheter tip temperature monitoring
as well as observed response. The end point of the ablation
procedure was the development of complete heart block.
The pacemaker implanted was a Pacesetter Trilogy SR
model 2250L (Pacesetter Inc., Sylmar, California) pro-
grammed VVIR, with rate-response functions optimized for
each patient. The minimum pacing rate was 80 to 90
beats/min for one month after ablation, with reprogram-
ming to a lower rate determined by the treating cardiologist
thereafter.
Concomitant medication. Patients continued all noncar-
diovascular medications unchanged. Use of warfarin or
antiplatelet agents was not altered by involvement in the
trial. Patients randomized to the AVJAP group ceased
ventricular rate-controlling drugs following the procedure.
Where patients were on beta-blockers, calcium channel
blockers, or digoxin for reasons other than ventricular rate
control, these drugs were continued.
Patient evaluation at each visit. At baseline (at the end of
the three-month lead-in period), patients had an exercise
(treadmill) test, 24-h ambulatory electrocardiogram (ECG),
and echocardiogram. One month after randomization, pa-
tients had an exercise test and 24-h ambulatory ECG. Six
and 12 months after randomization patients had an exercise
test, 24-h ambulatory ECG, and echocardiogram. A mod-
ified Bruce protocol, more aggressive in terms of slope and
speed increments than a standard Bruce protocol, was used
for exercise testing in order to determine the peak exercise
heart rate in an efficient way. Complete two-dimensional
color Doppler echocardiography was performed. Left ven-
tricular volumes and ejection fraction were calculated using
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Teicholz formula. The mean of 10 consecutive cardiac
cycles was used for patients in AF and three cardiac cycles
for patients in paced rhythm.
Quality-of-life assessment (Appendix). Patients com-
pleted health-related QoL questionnaires at baseline, six
months, and 12 months. The following questionnaires were
administered: the Assessment of Quality of Life Question-
naire (AQoL) (7), the CAST Quality of Life Questionnaire
(8), and the Sickness Impact Profile (SIP) (9).
Statistical analysis. Independent statistical analysis was
undertaken by the biostatistical consulting service of the
University of Western Australia (demographic, cardiac
function, and ventricular rate data) and the Centre for
Health Program Evaluation (QoL data). Data were ana-
lyzed using the SAS software package. The intent-to-treat
principle was used for all analyses. Continuous variables
were compared using the t test and categorical variables
were compared using Fisher’s exact test. The QoL ques-
tionnaires were scored according to rules of the original
authors. The QoL data were analyzed using the Mann-
Whitney U test (2-sided) for nonparametric independent
samples; because a large number of statistical tests were
performed, only p values0.01 were considered statistically
significant. For all data other than the QoL data, a p value
0.05 was considered statistically significant. A parametric
two-sample t test was used at each time point to compare
the mean values for medication (MED) group versus
AVJAP group. The hypothesis we were testing was that
there was no difference in the mean values for the two
groups at each time point.
RESULTS
Study population (Table 1). After randomization, 49
patients were allocated to the AVJAP group and 50 to the
MED group. As outlined in Table 1, the two groups were
well matched for age, gender ratio, structural heart disease,
ischemic heart disease, hypertension, symptom frequency,
and duration of AF.
Patient flow (Fig. 1). The majority of patient withdrawals
were among the AVJAP group before the ablation proce-
dure; the most common reason for withdrawal was the
patients “felt too well.” Two patients in the MED group
had AVJAP three and six months following randomization.
In both cases, the reason for crossover was “troublesome
symptoms in addition to a mean resting heart rate 80
beats/min or 150 beats/min during maximum exercise.”
Pharmacologic treatment. In the MED group the propor-
tion of patients on single ventricular rate-control agents and
combinations remained constant during the study. In con-
trast, 21 of 34 (62%) of the AVJAP group were not on any
ventricular rate-controlling drugs or combinations following
the ablation procedure. Hypertension and ischemic heart
disease were the most common reasons for AVJAP patients
to continue ventricular rate-controlling drugs.
Catheter ablation and pacemaker insertion. All patients
in the AVJAP group had successful ablation of the AV
junction at the initial procedure, with a median of two
applications of radiofrequency energy at 30 to 50 W using
the right heart approach. One patient developed a large
groin hematoma immediately following the procedure and
two patients developed pacemaker pocket hematomas; none
had any long-term adverse sequelae.
Echocardiographic evaluation of LVEF (Table 2). No
significant change in echocardiographically measured
LVEF was observed in either group during the study.
Treadmill test. The total exercise time did not improve
with ablation and pacing (Table 2). At one month post-
randomization, the AVJAP group had a higher resting heart
rates and lower maximum heart rates than the medical
treatment group. At six months post-randomization, the
AVJAP group had lower resting and maximum heart rates
than the MED group, whereas at 12 months post-
randomization, the AVJAP group had similar resting heart
rates and lower maximum heart rates than the medical
treatment group.
Holter monitor (Table 2). At one month post-
randomization, the AVJAP group had a higher minimum
and mean heart rates and lower maximum heart rates than
the MED group. At six months post-randomization, the
AVJAP group had a higher minimum and lower maximum
heart rate, whereas at 12 months post-randomization, the
Table 1. Baseline Characteristics of Study Population
MED
n  50
AVJAP
n  49 p Value
Global Population
n  99
Age, yrs 67.9  9 68  8.5 0.973 68  8.7
Male gender 72% 69% 0.775 71%
Ischemic heart disease 38% 43% 0.622 40%
Dilated cardiomyopathy 2% 6% 0.362 4%
Valvular heart disease 31% 35% 0.667 33%
Hypertension 38% 51% 0.192 44%
Diabetes 18% 10% 0.266 14%
Duration of AF (months) 78  131 58  66 0.322 68  104
Symptom frequency/month 4  5.3 3.5  0.92 0.352 4  3.8
Warfarin treatment 76% 78% 0.855 77%
Aspirin treatment 28% 35% 0.942 34%
AF  atrial fibrillation; AVJAP  atrioventricular junction ablation and pacing; MED  medication.
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AVJAP group had higher lower and mean heart rates and
lower maximum heart rates than the MED group.
Quality of life (Table 2). Even though the results of the
AQoL and SIP QoL questionnaires were not significantly
different for the two treatment groups, analysis of the
CAST QoL questionnaire data revealed that the AVJAP
group had significant improvements in quality of life. The
CAST QoL “symptom scale” ranges from 9 to 54, and the
AVJAP group had a reduction of 8 units on this scale at six
months whereas the medical treatment group had a reduc-
tion of 0.4 units (1% change). The reduction in symptoms
in the AVJAP group was maintained at 12 months, when
there was a 6.6-point reduction compared to baseline. The
observed relative risk reduction in symptoms at 12 months
was 18% (p  0.004). Global subjective semiquantitative
assessment of QoL using the “ladder of life” revealed that
Figure 1. Patient flow. AVJAP  atrioventricular junction ablation and pacing; MED  medication.
Table 2. Echocardiographic LVEF, Treadmill Test, and Holter Results
Number of Patients
Baseline 1 Month 6 Months 12 Months
MED 50 AVJAP 49 MED 50 AVJAP 36 MED 49 AVJAP 36 MED 47 AVJAP 34
Echocardiogram
LV ejection fraction (%) 57  14 55  16 — — 56  19 54  14 61  13 54  17
Treadmill test
Exercise time (min) 4.3  3 4.2  2.1 4.3  2.3 4.4  1.9 4.3  2 5.2  4 4.6  2 4.1  2
Exercise rest HR (beats/min) 79  23 82  25 81  16 87  8* 82  17 74  8* 77  19 75  8
Exercise maximum HR (beats/min) 151  45 158  33 154  31 115  14* 159  32 112  19* 153  36 112  17*
Holter
Minimum HR (beats/min) 41  12 41  17 44  14 80  12* 42  12 70  7* 39  9 70  9*
Mean HR (beats/min) 77  13 79  20 76  12 87  9* 76  17 77  6 71  11 76  7*
Maximum HR (beats/min) 154  37 152  41 147  44 117  14* 150  39 116  19* 152  37 117  16*
QoL
AQoL utility score 0.64  0.24 0.71  0.22 0.64  0.16 0.71  0.22 0.66  0.18 0.75  0.18
SIP total score 7.13  5.81 7.43  8.91 7.46  5.12 9.98  5.38 6.76  4.63 8.89  8.32
*p 0.05. Values are mean  SD
AQoL  Assessment of Quality of Life Questionnaire; HR  heart rate; LV  left ventricular; LVEF  left ventricular ejection fraction; SIP  Sickness Impact Profile.
Other abbreviations as in Table 1.
1700 Weerasooriya et al. JACC Vol. 41, No. 10, 2003
The AIRCRAFT Trial May 21, 2003:1697–702i
the AVJAP group reported a 6% better QoL at six months
and 12 months than the MED group (p  0.01).
Patients with baseline LVEF <45%. Nine patients in the
MED group and 10 patients in the AVJAP group had an
LVEF 45% at baseline. Predefined subgroup analysis
revealed no differences in LVEF, exercise tolerance, or heart
rates on treadmill testing or Holter monitoring for LVEF
45% patients.
Adverse events. Adverse events seen during the study are
outlined in Table 3. Comparing the two treatment groups,
there was no significant difference in the occurrence of any
adverse event. Two patients in the AVJAP group died
during the study. Both deaths were sudden out-of-hospital
events and occurred six months postablation in patients with
low LVEF. One patient in the MED group had a sudden
out-of-hospital event one month post-randomization.
DISCUSSION
Our study addresses the question posed by Wood et al. (10):
“what is the role of ablation and pacing therapy in the wider
population of patients with less symptomatic AF?” The
main findings of AIRCRAFT were that, in this patient
population, AVJAP had a neutral effect on cardiac function
measured by echocardiography or treadmill testing and QoL
was improved.
It is well established that, for patients with highly
symptomatic medically refractory permanent AF, AVJAP
provides superior symptom relief compared with pharma-
cologic management (2–6,10). Early nonrandomized stud-
ies suggested that AVJAP also improves cardiac function
(2–4), and the reasons suggested for this improvement were
reversal of tachycardia-related cardiomyopathy (11,12) as
well as the favorable hemodynamic effects of a regular
ventricular rhythm (13). Two prospective randomized trials
(5,6) reported results while the present study was underway.
Brignole et al. (5) showed a neutral effect on LVEF
following AVJAP in highly symptomatic permanent AF
patients with congestive heart failure, whereas Ueng et al.
(6) showed a modest improvement in the LVEF of patients
with a mean baseline LVEF of 44% and previously well-
controlled ventricular rates.
The AIRCRAFT patient population is unique because it
includes patients with mild to moderate symptoms. The
exclusion and inclusion criteria were chosen to determine if
there is a benefit of AVJAP in the wider population of
patients with permanent AF because AVJAP has not
previously been compared to pharmacologic ventricular rate
control in a controlled prospective manner in this popula-
tion. Subgroup analysis of patients with baseline LVEF
45 was prespecified in the study protocol because earlier
studies suggested that patients with impaired LVEF were
most likely to have improvement of LVEF following AV-
JAP (2–4).
Analysis of the prespecified subgroup of patients with
LVEF 45% failed to show any benefit of AVJAP on
echocardiographically measured LVEF. There were, how-
ever, very few patients in this subgroup, so these results must
be interpreted with caution. These findings contrast with
those of Twidale et al. (2), Edner et al. (3), and the “Ablate
and Pace” trial (4). In an uncontrolled study Twidale et al.
studied 14 patients with a mean LVEF of 42  3% and
found that this improved to 49  4% (p  0.02) following
AVJAP during a mean of nine months follow-up (2). The
study of Edner et al. lacked a control treatment arm, and
only post-hoc analysis of those patients with baseline LVEF
50% showed a significant improvement in LVEF (from
32  11% to 45  11%, p  0.001) a mean of 216 days
following AVJAP (3). The larger “Ablate and Pace” trial,
which was also nonrandomized, similarly showed an im-
provement in LVEF by post-hoc analysis of the patients,
with a baseline LVEF  45% (from 30  9% to 45  11%,
p  0.01) during one-year follow-up (4). The patient
populations in these studies were different in terms of
symptoms and ventricular rate control to the present AIR-
CRAFT study. The prospective randomized study of Ueng
et al. (6) was smaller than AIRCRAFT and showed an
improvement in acute hemodynamic variables as well as
LVEF. A possible reason for the difference in results
between our study and that of Ueng et al. (6) is the
difference in baseline LVEF of the two patient populations.
There has been recent interest in the importance of
synchrony of cardiac contraction in patients with impaired
LVEF. Patients who undergo AVJAP (with a right ventric-
ular apical pacing lead position) have iatrogenic cardiac
dyssynchrony that may counteract the beneficial effects of
rate and rhythm regulation. In patients with impaired
LVEF and permanent AF a biventricular pacing system
may be superior; this has not been studied in a controlled
prospective manner (14,15), however.
The mean ventricular rate measured by ambulatory elec-
trocardiography was higher in the AVJAP group at one
month because the minimum ventricular pacing rate was set
at 80 to 90 beats/min for one month following ablation.
This has been reported to reduce the risk of sudden cardiac
death (16). The ventricular rate during times of physical
activity was significantly better controlled in the AVJAP
group because, following ablation, the peak ventricular rate
and rate response function are programmable. Excessive
control of ventricular rate during exertion may result in
chronotropic incompetence, but this was not seen in the
Table 3. Adverse Events
MED AVJAP p
Death 1 2 0.617
Acute MI 1 2 0.617
Unstable angina 1 4 0.204
Hematoma 0 3 0.117
Pulmonary embolism 0 1 0.495
Drug reaction 3 0 0.242
Total 6 12 0.125
MI  myocardial infarction. Other abbreviations as in Table 1.
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AIRCRAFT trial, as evidenced by the fact that the exercise
duration by treadmill testing at six and 12 months follow-up
was not significantly different from the MED group.
The improvement in QoL was only apparent from
analysis of the CAST quality-of-life questionnaire data.
This questionnaire was chosen for the study because it was
designed for patients with arrhythmias. The AQoL and SIP
questionnaires are not disease specific and provide a global
impression of health-related QoL. It is apparent from our
study that the improvement in QoL following AVJAP is
due to symptom control, which was sensitively measured by
the CAST QoL questionnaire but not by the AQoL or SIP
questionnaires. It is unlikely that the improvement in QoL
was due to a placebo effect of having an invasive procedure,
as the results were durable during 12 months follow-up.
There was no significant difference in the mortality rate in
the two groups, although the study was not sufficiently
powered to examine this as an end point. There have been
concerns about sudden death following AVJAP (16,17),
possibly due to bradycardia-dependent QT prolongation
leading to ventricular fibrillation (16,17), but recent publi-
cations have reported that AVJAP is not associated with
increased risk of sudden cardiac death (18,19).
In summary, AVJAP is a safe and effective means of
controlling ventricular rate in permanent AF. In the wider
population of patients with permanent AF, having mild to
moderate symptoms, our study supports the use of this
treatment strategy when symptom control and improved
QoL are the primary goals. This strategy does not cause
deterioration of cardiac function.
Conclusions. In this trial, AVJAP for patients with mild to
moderately symptomatic permanent AF did not worsen
cardiac function during long-term follow-up and QoL was
improved.
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APPENDIX
QUALITY OF LIFE QUESTIONNAIRES USED IN AIRCRAFT
1. The Assessment of Quality of Life Questionnaire
(AQoL) (7). This questionnaire was designed using a
sample from the population of the state of Victoria (Aus-
tralia) as well as a sample from inpatients of a major public
teaching hospital in Melbourne (7). The AQol has been
validated by comparison with other established QoL ques-
tionnaires. AQoL consists of 12 questions and can be
completed within 10 min. The AQoL provides an overall
score for health-related quality of life, with a score of 1.0
representing the best possible quality of life and a score of 0
representing the worst possible quality of life.
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2. The CAST QoL questionnaire (8). This questionnaire
was developed for use in the cardiac arrhythmia suppression
trial (CAST). The questionnaire comprises 21 questions
obtained from established scales and has been shown to be
sensitive for measuring quality of life in cardiac patients. It
is relevant to the results of the AIRCRAFT study in that
this is the only questionnaire used that measures typical
arrhythmia symptoms (dizziness, irregular heartbeats, chest
pain, shortness of breath). The presence or absence and
frequency of specific symptoms are scored to give a “symp-
tom scale” with a higher number representing greater
symptoms and, therefore, worse QoL. The CAST question-
naire also has a “Ladder of Life” question, which is a
subjective, semiquantitative assessment by the patient of
his/her overall life satisfaction, with a score of 10 represent-
ing the best possible life and a score of 1 representing the
worst possible life. An example of the questionnaire is
provided in the appendix accompanying reference 8.
3. The Sickness Impact Profile (SIP) (9). The SIP is a
relatively complex and cumbersome QoL measurement tool
requiring 20 to 30 min to complete. As for the AQoL, this
questionnaire is not disease specific. The SIP total score is a
measure of overall health-related quality of life, with a
higher score representing better quality of life. The valida-
tion of the SIP is discussed in detail in reference 9.
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